A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3.
Vaccination of melanoma patients with tumor-specific antigens recognized by cytolytic T lymphocytes (CTL) produces significant tumor regressions in a minority of patients. These regressions appear to occur in the absence of massive CTL responses. To detect low-level responses, we resorted to antigenic stimulation of blood lymphocyte cultures in limiting dilution conditions, followed by tetramer analysis, cloning of the tetramer-positive cells, and T-cell receptor (TCR) sequence analysis of the CTL clones that showed strict specificity for the tumor antigen. A monoclonal CTL response against a MAGE-3 antigen was observed in a melanoma patient, who showed partial rejection of a large metastasis after treatment with a vaccine containing only the tumor-specific antigenic peptide. Tetramer analysis after in vitro restimulation indicated that about 1/40,000 postimmunization CD8(+) blood lymphocytes were directed against the antigen. The same TCR was present in all of the positive microcultures. TCR evaluation carried out directly on blood lymphocytes by PCR amplification led to a similar frequency estimate after immunization, whereas the TCR was not found among 2.5 x 10(6) CD8(+) lymphocytes collected before immunization. Our results prove unambiguously that vaccines containing only a tumor-specific antigenic peptide can elicit a CTL response. Even though they provide no information about the effector mechanisms responsible for the observed reduction in tumor mass in this patient, they would suggest that low-level CTL responses can initiate tumor rejection.
Coulie
P G
PG
Cellular Genetics Unit, Institute of Cellular Pathology, Cliniques Universitaires Saint-Luc, Université de Louvain, Brussels B1200, Belgium. coulie@gece.ucl.ac.be
Karanikas
V
V
Colau
D
D
Lurquin
C
C
Landry
C
C
Marchand
M
M
Dorval
T
T
Brichard
V
V
Boon
T
T
D000951:Antigens, Neoplasm; D001483:Base Sequence; D019496:Cancer Vaccines / Q000235:genetics / Q000627:therapeutic use*; D002999:Clone Cells / Q000276:immunology; D003602:Cytotoxicity, Immunologic; D017931:DNA Primers / Q000235:genetics; D006801:Humans; D016130:Immunophenotyping; D066298:In Vitro Techniques; D008545:Melanoma / Q000235:genetics / Q000276:immunology* / Q000556:secondary / Q000628:therapy*; D009363:Neoplasm Proteins / Q000235:genetics / Q000627:therapeutic use*; D016133:Polymerase Chain Reaction; D016693:Receptors, Antigen, T-Cell, alpha-beta / Q000235:genetics; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014611:Vaccination
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D017931:DNA Primers; C072013:MAGEA3 protein, human; D009363:Neoplasm Proteins; D016693:Receptors, Antigen, T-Cell, alpha-beta